FDA Clears Prescription Digital Behavioral Therapeutic for Type 2 Diabetes

07/21/2023

Article Excerpt: The Food and Drug Administration (FDA) has cleared AspyreRx™, a prescription digital behavioral therapeutic device for adults with type 2 diabetes.The device is intended to provide cognitive behavioral therapy (CBT), as an adjunct to standard of care, to patients aged 18 years and older with type 2 diabetes under the care of a health care provider. Prescribed in 90-day increments, the digital therapeutic delivers CBT through a mobile application in a weekly, step-by-step process to help patients improve glycemic control.

Full Article: https://tinyurl.com/hx63366n

Article Source: Psychiatry Advisor